Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia
2002 (English)In: Medical Oncology, ISSN 1357-0560, Vol. 19, no 4, 277-80 p.Article in journal (Refereed) Published
Alemtuzumab (Campath-1H) is a humanized CD52 monoclonal antibody that targets normal as well as malignant B- and T-lymphocytes. Alemtuzumab has significant antitumor activity in chronic lymphocytic leukemia (B-CLL) but also induces immunosuppression. We describe a case of fatal adenovirus infection in a heavily pretreated patient with fludarabine-refractory B-CLL receiving alemtuzumab therapy, drawing attention to the fact that also viruses other than cytomegalovirus (CMV) and herpes simplex (HSV) need to be considered in B-CLL patients with fever of unknown origin while on alemtuzumab treatment.
Place, publisher, year, edition, pages
2002. Vol. 19, no 4, 277-80 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-105422DOI: 10.1385/MO:19:4:277PubMedID: 12512923OAI: oai:DiVA.org:uu-105422DiVA: diva2:221202